Related Experiment Videos
Activation of c-ras oncogenes by mutations and amplification
Annals of Clinical Research
|January 1, 1986
Summary
Approximately 15% of human tumors harbor c-ras oncogenes, often due to point mutations. The clinical importance of these oncogenes remains under investigation.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The c-ras oncogene is implicated in various human cancers.
- Activating mutations in c-ras oncogenes are frequently observed.
Purpose of the Study:
- To summarize the prevalence and nature of c-ras oncogene involvement in human tumors.
- To highlight the current understanding and limitations regarding the clinical significance of c-ras oncogenes.
Main Methods:
- Detection of c-ras oncogenes using various molecular methods.
- Analysis of point mutations within the c-ras gene and their protein products.
Main Results:
- C-ras oncogenes are present in approximately 15% of all human tumors, including carcinomas, sarcomas, melanomas, and leukaemias.
- The most common activating lesion is a point mutation affecting critical amino acid residues in the c-ras protein.
Conclusions:
- C-ras oncogenes are a common feature in a significant proportion of human malignancies.
- Further research is required to elucidate the precise clinical significance of c-ras oncogenes in cancer patients.